Pfizer shares fall after it forecasts 2026 revenue below estimates

Pfizer said it expects 2026 revenue of $59.5 billion to $62.5 billion and adjusted EPS of $2.80–$3, figures it described as slightly below Wall Street estimates and which sent shares down about 5.1%. Management attributed the shortfall to a roughly $1.5 billion decline in COVID-19 product sales (sales of COVID products are expected to fall to about $5 billion from $6.5 billion this year, with Paxlovid declining more than Comirnaty) and roughly $1.5 billion of revenue pressure from imminent loss of exclusivity; excluding those factors Pfizer projects about 4% operational growth and assumes infection rates will ease, particularly in Q1. Executives said planned $7.2 billion in realignment cost savings plus continued investment in oncology and obesity programs should position the company for stronger top-line expansion by 2029–2030.

Analysis

Pfizer guided 2026 revenue of $59.5 billion to $62.5 billion and adjusted EPS of $2.80 to $3, figures the company said are slightly below Wall Street estimates; the stock fell 5.1% on the announcement. Management quantified drivers as roughly $1.5 billion of lower COVID-19 product sales and about $1.5 billion of revenue pressure from imminent loss of exclusivity, reasons cited for the guidance shortfall.

The company expects COVID-19 sales of about $5 billion in 2026 versus $6.5 billion this year and warned Paxlovid will decline more significantly than Comirnaty, with Paxlovid described as volatile and closely linked to infection rates; the forecast assumes infection rates will decline, particularly in Q1. Excluding COVID and LOE impacts, Pfizer projects approximately 4% operational growth, indicating core business resilience but near-term topline headwinds.

Management is pursuing $7.2 billion of realignment cost savings while continuing investments in oncology and obesity to drive stronger expansion by 2029–2030, but the company warned LOE impacts will peak in 2028. Key risks that could alter the outlook are a slower-than-expected decline in COVID infections, greater Paxlovid volatility, or deeper generic erosion before cost-savings and pipeline investments materialize, which explains the moderately negative market sentiment.

Key Decisions for Investors

• Consider trimming or rebalancing near-term PFE exposure after guidance missed estimates and shares dropped 5.1%, given 2026 revenue guidance of $59.5–$62.5 billion and adj. EPS $2.80–$3
• Monitor Q1 infection-rate data and Paxlovid sales closely because the forecast assumes declining infections; adjust positions if infection trends or Paxlovid demand deviate from management's assumptions
• Re-evaluate conviction in Pfizer's mid-to-long-term thesis by requiring evidence of delivery on the $7.2 billion realignment savings and progress in oncology/obesity before adding size
• Use hedges or options to protect against near-term downside tied to infection-rate volatility and accelerating generic competition, and watch for clarity around LOE impacts as they approach a 2028 peak